{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/benzodiazepine-z-drug-withdrawal/background-information/complications/","result":{"pageContext":{"chapter":{"id":"d110deb7-70d0-5c76-8606-a9af49e97f91","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field e7dd3ffa-5168-4d2e-b1aa-a95e00bad0df --><h2>What are the complications of long-term use?</h2><!-- end field e7dd3ffa-5168-4d2e-b1aa-a95e00bad0df -->","summary":"","htmlStringContent":"<!-- begin item e3dc401e-21ef-4abb-8e1d-a95e00bad04e --><!-- begin field 6a3dce22-e8af-4aa9-86ad-a95e00bad0df --><ul><li><strong>The long-term use of benzodiazepines or z-drugs is associated with a number of health conditions and an increased risk of death:</strong><ul><li>Over-sedation from long-term use can increase the risk of falls and accidents on the road and in the home.</li><li>Poisoning from overdose may contribute to increased mortaliity risk.</li><li>Studies have shown that users of hypnotics exhibit an increased risk of cancer that does not appear to be fully explained by preferential prescribing in people with poor health.</li><li>In England and Wales during 2015 there were 366 deaths involving benzodiazepines, with a mortality rate of 6.5 deaths per million population, similar to the rate in 2014.</li><li>In England and Wales, the numbers of deaths involving zopiclone or zolpidem were 87 in 2015, and 100 in 2014.</li></ul></li><li><strong>Long-term use of benzodiazepines or z-drugs (usually more than 4 weeks) may be associated with:</strong><ul><li>Tolerance — a higher dose is required to obtain the initial effect.</li><li>Dependence — the person feels they need the medication to carry out day-to-day activities, and/or withdrawal symptoms occur upon stopping or dose reduction.<ul><li>Benzodiazepine withdrawal symptoms include sweating, insomnia, headache, tremor, nausea, palpitations, anxiety, depression, panic attacks or rarely psychosis and/or seizures. These symptoms may mimic the original anxiety disorder.</li><li>Z-drug withdrawal symptoms include insomnia/sleep disturbance, anxiety, depression, impaired concentration, abdominal cramps, palpitations, and perceptual disturbances (such as hypersensitivity to physical, visual and auditory stimuli).</li><li>The risk of withdrawal symptoms increases with longer use, higher dosage, and higher potency. </li></ul></li></ul></li><li><strong>Other effects of long-term use of benzodiazepines include:</strong><ul><li>Cognitive effects, anxiety, agarophobia, emotional blunting, reduced coping skills, and amnesia. </li><li>Reduced social functioning due to effects on memory, reduced ability to remember new people, appointments etc.</li><li>Depression, either for the first time, or aggravation of pre-exisiting depression with possible precipitation of suicidal tendencies.</li></ul></li><li><strong>Note: older people are more vulnerable to the CNS depressant effects of benzodiazepines, possibly leading to confusion, night wandering, amnesia, ataxia, and hangover effects. Impaired cognitive function and memory may be wrongly diagnosed as dementia.</strong></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/references/\">Kripke et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/references/\">Ford and Law, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/benzodiazepine-z-drug-withdrawal/references/\">All Wales Medicines Strategy Group, 2016</a>]</p><!-- end field 6a3dce22-e8af-4aa9-86ad-a95e00bad0df --><!-- end item e3dc401e-21ef-4abb-8e1d-a95e00bad04e -->","topic":{"id":"e3f1abb8-a968-53c3-bc6a-12e1b2886ed2","topicId":"35151ccb-5966-4e29-97a4-191f3f2aef6a","topicName":"Benzodiazepine and z-drug withdrawal","slug":"benzodiazepine-z-drug-withdrawal","lastRevised":"Last revised in January 2019","chapters":[{"id":"ddeb227b-ec5e-5a69-b033-23d16e492302","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ca1d0037-207c-5656-8c1a-64eb8f8a6adf","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4f9475f8-9d93-5b3d-9cc7-66f08d975494","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"33c4d415-a5bf-586c-af94-95833f29167f","slug":"changes","fullItemName":"Changes"},{"id":"814181c9-c71c-54f0-a9f2-a7b2a5f73459","slug":"update","fullItemName":"Update"}]},{"id":"2237f5ce-b47f-5f59-80d4-2098a2fafae1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"14f4d723-2346-5509-b69f-ec1690c54f89","slug":"goals","fullItemName":"Goals"},{"id":"978d3882-5b77-58d0-9081-5f1879a2e244","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df6950b2-9910-5c3e-9f7e-a89c359ba5cf","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f78c4bb6-5d1b-516c-acb6-5a8a6add79ec","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1d88ca0e-4d2b-56ae-9602-a213d4c8767e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00453e06-07ba-5d13-a4f0-dfd3b6e7dfa4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"058ea4e2-b85f-5dbf-885b-f3a39f06d48c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"24a95463-c4af-5572-b06f-acf2f15c47d1","slug":"definition","fullItemName":"Definition"},{"id":"fbb9e10e-ed3c-51d5-b3fa-e2d482b83413","slug":"prevalance","fullItemName":"Prevalance"},{"id":"32dfcd69-3d5d-5897-bd8f-cee84b53b670","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d110deb7-70d0-5c76-8606-a9af49e97f91","slug":"complications","fullItemName":"Complications"},{"id":"c26626ad-6167-542c-98fe-a2ff03221e61","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a846d324-cab9-57dd-a619-3bf18b540356","fullItemName":"Management","slug":"management","subChapters":[{"id":"80278306-0d51-5a46-abdb-638c41fd825d","slug":"benzodiazepine-z-drug-withdrawal","fullItemName":"Scenario: Benzodiazepine and z-drug withdrawal"}]},{"id":"b14f0631-9202-58fa-a823-a1f92f05ac08","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"22b2c65a-e4c1-5d8f-9260-f639540d94cb","slug":"diazepam","fullItemName":"Diazepam"}]},{"id":"3833e4c8-dbff-59bf-92ae-bd1c772444bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d4659376-3ee7-5273-9fe9-08f5ce86d7d8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9bd84543-e92f-541d-80e5-17f0b36fcb90","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d3ade608-7d7c-5174-9cad-8cecde797cd1","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3e7141fe-bc43-5b07-81c4-1fb82ca82b2c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5c9aad6e-7321-5cc2-bad0-677e761afc6e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7a323840-12e0-545e-87de-461171f81997","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"351aac8e-ed32-587e-88b8-27ee3fa69f10","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"058ea4e2-b85f-5dbf-885b-f3a39f06d48c","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}